Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status

NCT06713161 is registered in ClinicalTrials.gov with Yunnan Cancer Hospital as lead sponsor.

NCT NCT06713161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06713161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
Lead sponsor
Yunnan Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2024
Completion date
December 25, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, margin assessment, metastases, sentinel lymph node